A rapid screening system to determine drug affinities for the intestinal dipeptide transporter 2: Affinities of ACE inhibitors

International Journal of Pharmaceutics

Volumn 210, Issue 1-2, 2000, Pages 29-44

  Moore, Vanessa A ^a   Irwin, William J ^a   Timmins, Peter ^a,b   Lambert, Peter A ^a   Chong, Saeho ^b   Dando, Sandra A ^b   Morrison, Richard A ^b  

^a ASTON UNIVERSITY   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

ACE inhibitors; Caco 2 cells; Dipeptide transporter system (DTS); Dipeptides; Peptidomimetic agents; Structure activity relationships

Indexed keywords

4 CYCLOHEXYLCAPTOPRIL; BENAZAPRILAT; BENAZEPRIL; CAPTOPRIL; CARBOXYLIC ACID; CARRIER PROTEIN; CERANAPRIL; CERANAPRIL DERIVATIVE; CILAZAPRIL; DIPEPTIDE TRANSPORTER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; FOSINOPRILAT; GLYCYLPROLINE; LISINOPRIL; PERINDOPRIL; PHOSPHINIC ACID DERIVATIVE; PROLINE; QUINAPRIL; S BENZOYLCAPTOPRIL; TRITIUM; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL STRAIN CACO 2; CONTROLLED STUDY; DEVICE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ESTERIFICATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; ISOTOPE LABELING; LIPOPHILICITY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SURFACE CHARGE;

ALGORITHMS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATP-BINDING CASSETTE TRANSPORTERS; CACO-2 CELLS; CULTURE MEDIA; DIPEPTIDES; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; ORGANOPHOSPHORUS COMPOUNDS; PROLINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034605977     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00564-0     Document Type: Article

References (38)

1. Structural requirements for the intestinal mucosal-cell peptide transport; The need for N-terminal a-amino group
2. The use of the intestinal epithelial cell culture model, Caco-2 in pharmaceutical development
3. +/peptide symporter (PEPT1), and the uptake into Caco-2 cell monolayers and the transepithelial flux
4. Oral absorption of β-lactams by intestinal peptide transport proteins
5. Uptake of the cephalosporin, cephalexin, by the dipeptide transport carrier in the human intestinal cell line, Caco-2
6. Cefaclor uptake by the proton-dependent dipeptide transport carrier of human intestinal Caco-2 cells and comparison to cephalexin uptake
7. Captopril kinetics
8. Intestinal absorption mechanisms of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: Lisinopril and SQ 29852
9. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitors pro drugs: Enalapril and Fosinopril
10. Applications of the Caco-2 model in the design and development of orally active drugs: Elucidation of biochemical and physical barriers posed by the intestinal epithelium
11. Uptake and transepithelial transport of the orally absorbed cephalosporin cephalexin, in the human intestinal cell line
12. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter
13. Structural requirements for the interaction with the oligopeptide transporter in Caco-2 cells
14. Passive and carrier-mediated intestinal absorption components of captopril
15. Mechanisms of transport of quinapril in Caco-2 cell monolayers: Comparison with cephalexin
16. Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line Caco-2: Specific transport systems in apical and basolateral membranes
17. Absorption of ACE inhibitors from the small intestine and colon
18. The intestinal oligopeptide transporter
19. Distribution of the dipeptide transporter system along the gastrointestinal tract of rats based on the absorption of a stable and specific probe, SQ-29852
20. Systematic evaluation of the structural requirements for the intestinal dipeptide transporter system
21. A rapid screening system to determine drug affinities for the intestinal dipeptide transporter 1: System characterisation
22. Suitability of enalapril as a probe of the dipeptide transporter system: In vitro and in vivo studies
23. Uptake and Transport of an ACE-inhibitor (SQ 29852) by Caco-2 Cells
24. Uptake and transport of the ACE-inhibitor Ceronapril (SQ 29852) by monolayers of human intestinal absorptive (Caco-2) cells in vitro
25. Characterisation of the oral absorption of several aminopenicillins: Determination of intrinsic membrane absorption parameters in the rat intestine in situ
26. +-coupled uphill transport of aminocephalosporins via the dipeptide transport system in rabbit intetsinal brush-border membranes
27. Configuration and preferential solid-state conformations of perindoprilat (S-9780). Comparison with the crystal structures of other ACE inhibitors and conclusions related to structure activity relationships
28. Enalapril and Lisinopril
29. +-dependent transepithelial transport of cephalosporins in Caco-2 cells
30. Structure-transport relationships for the intestinal small peptide carrier: Is the carbonyl group of the peptide bond relevant for transport
31. Renal handling of captopril - Effect of probenecid
32. Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: Enalapril, enalaprilat and lisinopril
33. Molecular determinants of recognition for the intestinal peptide carrier
34. Recognition of α-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells
35. Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells
36. The effect of a meal, at various times relative to drug administration, on the bioavailability of captopril
37. Noncompetitive inhibition of cephradine uptake by enalapril in rabbit intestinal brush-border membrane vesicles: An enalapril-specific inhibitory binding site on the peptide carrier
38. Stability and in vitro absorption of captopril, enalapril and lisinopril across the rat intestine